Documents - 2019

Displaying 1 - 16 of 16 results
 
Collapse Filters
 
Expand Filters         +
July 16, 2019

Statement Before House of Representatives Subcommittee on "Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl"

Statement of Matthew Donahue before the House of Representatives, Energy and Commerce Committee, Subcommittee on Oversight and Investigations for a hearing entitled, Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl.

June 4, 2019

Greg Cherundolo The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Judiciary Committee for hearing entitled:  The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order.

May 31, 2019

Updating the Prescription Opioid Threat in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...

April 25, 2019

SFL8 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southwest Laboratory (SFL8).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL7 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Western Laboratory (SFL7).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL6 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the South Central Laboratory (SFL6).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL5 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the North Central Laboratory (SFL5).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL4 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southeast Laboratory (SFL4).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL3 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Mid-Atlantic Laboratory (SFL3).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL2 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Northeast Laboratory (SFL2).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

SFL1 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Special Testing and Research Laboratory (SFL1).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated quantitative methods.  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 9, 2019

Greg Cherundolo Unprecendented Migration at the U.S. Southern Border: Perspectives from the Frontline

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Homeland Security and Governmental Affairs Committee

February 21, 2019

Acting Administrator Uttam Dhillon, Museum of Natural History and Science

Acting Administrator Uttam Dhillon at the Drugs: Cost and Consequences Press Conference, Museum of Natural History and Science, Albuquerque, New Mexico

February 19, 2019

Athletes and Opioids Poster

What is prescription pain reliever misuse? As defined by the National Survey on Drug Use and Health, it’s “use without a prescription of one’s own or use at a higher dosage or more often than prescribed.” Prescription opioid addiction – stemming from misuse – has hit the nation hard in recent years. Unfortunately, high school student-athletes can be especially vulnerable to prescription painkiller misuse. This poster encourages teens, parents and other caregivers, and educators to know the risks around misusing pain pills.

February 5, 2019

Acting Administrator Uttam Dhillon, University of South Carolina-Aiken

Acting Administrator Uttam Dhillon at the University of South Carolina-Aiken, Chancellor’s Signature Speaker Series Aiken, South Carolina

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice